CSF2 and metastatic melanoma: The administration of granulocyte-macrophage colony-stimulating factor (GM-CSF)-based vaccines in patients with metastatic melanoma noticeably increases the number of CD14+HLA-DR−/low MDSCs in the peripheral blood [59].